Archive for December, 2009

Tighter rules sought against using anti-psychotic drugs to chemically restrain the frail & elderly

Sunday, December 20th, 2009

Sam Roe and Christina Jewett
Chicago Tribune
December 20, 2009

Health advocates are calling for tough new rules on the use of anti-psychotic drugs in Illinois nursing homes, including tighter controls on doctors who prescribe the powerful medications.

“Medical care should help you get better, not get worse,” said Wendy Meltzer of Illinois Citizens for Better Care, an advocacy group for nursing home residents.

A Tribune investigation recently showed how many frail and vulnerable Illinois nursing home residents have been unnecessarily dosed with anti-psychotics, leading to harm and an increased risk of death. One psychiatrist, the Tribune found in a joint investigation with ProPublica, provided assembly-line care to thousands of mentally ill patients.

The advocates want Gov. Pat Quinn’s Nursing Home Safety Task Force to address these problems. While the task force has focused on violent felons housed in nursing facilities, chairman Michael Gelder said the group will also target the misuse of psychotropic drugs.

Read entire article: http://www.chicagotribune.com/health/chi-psychotropics-reformdec20,0,3977364.story

« Return to news items


Share

Breaking News: Florida Psychiatrist who wrote 153 psych drug prescriptions per day is now under federal investigation

Thursday, December 17th, 2009

Kelli Kennedy
Miami Herald
December 17, 2009

Medicare has stopped reimbursing a Miami doctor who prescribed about 96,685 mental health drugs to Medicaid patients in 18 months.

According to state records, Dr. Fernando Mendez Villamil wrote an average of 153 prescriptions to adults and children every day between 2007 and 2009. That figure is nearly twice the number of the second highest prescriber on the list, who wrote 53,018 prescriptions over the same time period.

Read entire article: http://www.miamiherald.com/news/florida/AP/story/1387071.html

« Return to news items


Share

Psychiatrist comes under fire from Senator Grassley for writing 96,685 psych drug prescriptions – about 153 per day

Wednesday, December 16th, 2009

John Dorschner
Miami Herald
December 16, 2009

U.S. Sen. Charles Grassley, R-Iowa, has written a biting letter to top government officials using the example of a Miami psychiatrist who writes more than 100 prescriptions a day to raise questions about what federal officials are doing to monitor over-utilization of healthcare services.

The letter does not mention Fernando Mendez-Villamil by name, but it cites documents from the Florida Agency for Healthcare Administration about a prescriber who wrote 96,685 prescriptions from the last quarter of 2007 through the first quarter of 2009 for Medicaid patients.

AHCA records independently obtained by The Miami Herald indicate that is Mendez-Villamil, who wrote nearly twice as many prescriptions for mental health drugs as the No. 2 Medicaid prescriber in the state.

“ I note with alarm that the top Medicaid prescriber during that time wrote 96,685 prescriptions for mental health drugs,“ Grasley wrote. “That means that this physician wrote approximately 153 prescriptions each and every day, assuming he did not take vacations.”

Read entire article: http://www.miamiherald.com/business/breaking-news/story/1384786.html

« Return to news items


Share

Paxil birth defect settlement tops list of “most impactful” lawsuit settlements for 2009

Tuesday, December 15th, 2009

Kristine B.
LawyersandSettlements.com
December 15, 2009

We’re in the countdown to year-end and looking over some of the more impactful settlements LawyersAndSettlements.com has covered over the past year. When we’re talking impactful, everyone around here has an opinion—so we had to throw in some criteria. To get the nod for impact, a settlement had to be one of two things: 1. High dollar value; or 2. Precedent-setting—or at least have the potential to influence similar cases to follow. (Sounds simple, but you try getting Stephen, John, Jaime, Michelle and Ben to settle in on just 7 settlements with just those criteria…) So here we go…7 game-changing settlements for ‘09…

1) Family takes on GlaxoSmithKline

Michelle David filed a lawsuit against GlaxoSmithKline, alleging the company’s antidepressant, Paxil was responsible for her son’s birth defects. David said she had taken Paxil while pregnant and was not aware of the potential side effects. GlaxoSmithKline said that birth defects occur in between three and five percent of all live births, regardless of Paxil use.

Read entire article: http://www.lawyersandsettlements.com/blog/7-game-changing-settlements-of-2009-02165.html

« Return to news items


Share

That British Drug Maker Glaxo’s $1 Billion Paxil Settlements Were Disclosed by Press – Not Drug Maker – Is Cause for Concern

Tuesday, December 15th, 2009

Jim Edwards
BNET
December 15, 2009

British drug company GlaxoSmithKline (GSK) has paid $1 billion to settle lawsuits related to Paxil. The fact that it was disclosed by Bloomberg and not the company itself illustrates how lousy financial disclosure rules are in Europe and why drug companies based there cannot be trusted to tell the truth about what is going on with their litigation liabilities and, by extension, the safety of their drugs.

Bloomberg got the $1 billion number by piecing together litigation records, analysts’ reports and GSK’s own partial statements on the issue. But compare the Paxil situation with those faced by Eli Lilly (LLY) and AstraZeneca (AZN). Both companies have been engaged in litigation that has cost them billions (over the antipsychotics Zyprexa and Seroquel, respectively). And both companies have disclosed the full legal bill attached to those suits. (It’s more than $3.3 billion for Lilly and $1.1 billion for AZ.

Those numbers were disclosed in both companies’ earnings reports. Interestingly, Lilly disclosed them because it was required to report anything “material” by the SEC — it’s an American company and that’s the law. Fines and prosecutions await American firms that fail to report bad news.

Read entire article: http://industry.bnet.com/pharma/10005807/gsks-1b-paxil-problem-highlights-murky-disclosures-from-euro-drug-companies/

« Return to news items


Share

NAMI – the ‘patients rights’ group which is really funded by & a major lobbying arm of Psycho/Pharma – is on the defensive

Tuesday, December 15th, 2009

Ed Silverman
Pharmalot
December 15, 2009

The National Alliance on Mental Illness is on the defensive. After reports that most donations made to the big advocacy group came from drug makers in recent years, NAMI agreed to disclose its funding sources. The disclosure, however, came after protracted criticism of NAMI for coordinating lobbying efforts with drug makers and pushing legislation that also benefits the pharma industry.

The embarassing episode prompted NAMI’s executive director, Michael Fitzpatrick, to acknowledge industry donations were excessive and that things would change. Meanwhile, board member Richard Lamb resigned over the issue, complaining little was changing, saying NAMI’s dependence on drugmakers made some actions impossible, such as warning against the use of some mental health drugs with life-threatening side effects.

Read entire article: http://www.pharmalot.com/2009/12/nami-runs-a-survey-on-pharma-funding/?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+Pharmalot+(Pharmalot)

« Return to news items


Share

50 to 79 Year-old Women on Antidepressants Are 45% More Likely to Have a Stroke and Are at 32% Higher Risk of Death

Monday, December 14th, 2009

Deirdre Branley
Eurekalert.org
December 14, 2009

Postmenopausal women who take antidepressants face a small but statistically significant increased risk for stroke and death compared with those who do not take the drugs. The new findings are from the federally-funded, multi-institution, Women’s Health Initiative Study sponsored by the National Institutes of Health, and the results are published in the December 14 online edition of Archives of Internal Medicine.

Senior author Sylvia Wassertheil-Smoller, Ph.D., is a principal investigator in the Women’s Health Initiative and is division head of epidemiology and professor of epidemiology & population health at Albert Einstein College of Medicine of Yeshiva University. In addition to Einstein, other institutions involved in the study were Massachusetts General Hospital, where the lead author of the paper, Jordan W. Smoller, M.D., Sc.D., is based. He is also associate professor of psychiatry in the Harvard Medical School. Also contributing to the study are researchers from the University of California San Diego, the University of Washington, the University of Hawaii, the University of Iowa, the University of Massachusetts Medical School, and Emory University School of Medicine.

The study examined data from 136,293 study participants, aged 50 to 79, who were not taking antidepressants when they enrolled in the study, and who were followed for an average of six years. Data from 5,496 women who were taking antidepressants at their first follow-up visit were compared with data from 130,797 not taking antidepressants at follow-up. The researchers compared the two groups with respect to the incidence of fatal or nonfatal stroke, fatal or nonfatal heart attack and death due to all causes.

The researchers found no difference in coronary heart disease (defined as fatal and non-fatal heart attacks). However, they did observe a significant difference in stroke rates: antidepressant users were 45 percent more likely to experience strokes than women who weren’t taking antidepressants.

The study also found that when overall death rates (all-cause mortality) were compared between the two groups, those on antidepressants had a 32 percent higher risk of death from all causes compared with non-users.

Read entire article: http://www.eurekalert.org/pub_releases/2009-12/aeco-ami121009.php

« Return to news items


Share

Glaxo Said to Have Paid $1 Billion in Paxil Suits Including About $390 Million for Suicides/Attempted Suicides Linked to Drug

Monday, December 14th, 2009

Jef Feeley and Margaret Cronin Fisk
Bloomberg.com
December 14, 2009

GlaxoSmithKline Plc has paid almost $1 billion to resolve lawsuits over Paxil since it introduced the antidepressant in 1993, including about $390 million for suicides or attempted suicides said to be linked to the drug, according to court records and people familiar with the cases.

As part of the total, Glaxo, the U.K.’s largest drugmaker, so far has paid $200 million to settle Paxil addiction and birth-defect cases and $400 million to end antitrust, fraud and design claims, according to the people and court records.

The $1 billion “would be worse than many people are expecting,” said Navid Malik, an analyst at Matrix Corporate Capital in London. “I don’t think this is within the boundaries of current assumptions for analysts.”

The London-based company hasn’t disclosed the settlement total in company filings. It has made public some accords. Glaxo’s provision for legal and other non-tax disputes as of the end of 2008 was 1.9 billion pounds ($3.09 billion), according to its latest annual report. This included all legal matters, not just Paxil. The company said 112 million pounds of this sum would be “reimbursed by third-party issuers.”

Read entire article: http://www.bloomberg.com/apps/news?pid=20601103&sid=aWNKB4YPWjIY

« Return to news items


Share

US Kids Represent Psychiatric Drug Goldmine

Monday, December 14th, 2009

Truthout
Evelyn Pringle
December 12, 2009

Prescriptions for psychiatric drugs increased 50 percent with children in the US, and 73 percent among adults, from 1996 to 2006, according to a study in the May/June 2009 issue of the journal Health Affairs. Another study in the same issue of Health Affairs found spending for mental health care grew more than 30 percent over the same ten-year period, with almost all of the increase due to psychiatric drug costs.

On April 22, 2009, the US Agency for Healthcare Research and Quality reported that in 2006 more money was spent on treating mental disorders in children aged 0 to 17 than for any other medical condition, with a total of $8.9 billion. By comparison, the cost of treating trauma-related disorders, including fractures, sprains, burns, and other physical injuries, was only $6.1 billion.

In 2008, psychiatric drug makers had overall sales in the US of $14.6 billion from antipsychotics, $9.6 billion off antidepressants, $11.3 billion from antiseizure drugs and $4.8 billion in sales of ADHD drugs, for a grand total of $40.3 billion.

The path to child drugging in the US started with providing adolescents with stimulants for ADHD in the early 80s. That was followed by Prozac in the late 80s, and in the mid-90s drug companies started claiming that ADHD kids really had bipolar disorder, coinciding with the marketing of epilepsy drugs as “mood stablizers” and the arrival of the new atypical antipsychotics.

Read entire article: http://www.truthout.org/1213091

« Return to news items


Share

Senator Grassley tells TeenScreen Executive Director (& former head of NAMI) to disclose all TeenScreen pharma funding

Sunday, December 13th, 2009

United States Senate
Committee on Finance
Washington, D.C. 20510-6200

December 7, 2009

Via Electronic Transmission

Laurie Flynn
Executive Director
TeenScreen National Center for Mental Health Checkups at Columbia University
1775 Broadway, Suite 610
New York, NY 10019

Dear Ms. Flynn:

The United States Senate Committee on Finance (Committee) has jurisdiction over the Medicare and Medicaid programs and, accordingly, a responsibility to the more than 100 million Americans who receive health care coverage under these programs. As Ranking Member of the Committee, I have a duty to protect the health of Medicare and Medicaid beneficiaries and safeguard taxpayer dollars authorized by Congress for these programs.

For the last three years, the Committee has been looking into various aspects of the pharmaceutical industry, including consulting arrangements, and industry funding for Continuing Medical Education (CME). My inquiry was spurred, in part by press accounts documenting the lack of transparency in the relationships between the pharmaceutical industry and nonprofit organizations. For instance, in April 2008, The Wall Street Journal reported that industry representatives, including ten major drug
companies, formed a coalition to promote looser restrictions on off-label marketing. The coalition asked the National Alliance on Mental Illness (NAMI) to speak in favor of this issue.

On October 6th of this year, I sent letters to all fifty state chapters of NAMI asking them to disclose income from pharmaceutical companies. In that letter, I explained that NAMI National receives almost two-thirds of its funding from the drug industry.  I learned recently that a few days after I sent those letters, one of the founders of NAMI and member of the NAMI National Board of Directors emailed his resignation,
stating that he was shocked at NAMI’s reliance on pharmaceutical industry funding. In particular he said: “This financial dependency presents a number of problems.”

Read entire letter: http://www.psychsearch.net/Letter_to_TeenScreen.pdf

« Return to news items


Share